In JoVE (1)
Other Publications (1)
Articles by Felipe J. Núñez in JoVE
Immunoprecipitazione della cromatina nativo utilizzando neurosfere tumore del cervello murino Flor M. Mendez1, Felipe J. Núñez1,2, Rocío I. Zorrilla-Veloz3,4, Pedro R. Lowenstein1,2, Maria G. Castro1,2 1Department of Cell and Developmental Biology, University of Michigan Medical School, 2Department of Neurosurgery, University of Michigan Medical School, 3Cancer Research Summer Internship Program (CARSIP), Cancer Biology Program, University of Michigan Medical School, 4Department of Biology, University of Puerto Rico-Río Piedras Campus Meccanismi epigenetici sono frequentemente alterati nei gliomi. Immunoprecipitazione della cromatina poteva essere utilizzati per studiare le conseguenze delle alterazioni genetiche in glioma risultanti dalle modifiche in modificazioni istoniche che regolano la trascrizione di gene e la struttura della cromatina. Questo protocollo descrive immunoprecipitazione della cromatina nativo su neurosfere tumore del cervello murino.
Other articles by Felipe J. Núñez on PubMed
Mutated Chromatin Regulatory Factors As Tumor Drivers in Cancer Cancer Research. | Pubmed ID: 28062403 Genes encoding proteins that regulate chromatin structure and DNA modifications [i.e., chromatin regulatory factors (CRF)] and genes encoding histone proteins harbor recurrent mutations in most human cancers. These mutations lead to modifications in tumor chromatin and DNA structure and an altered epigenetic state that contribute to tumorigenesis. Mutated CRFs have now been identified in most types of cancer and are increasingly regarded as novel therapeutic targets. In this review, we discuss DNA alterations in CRFs and how these influence tumor chromatin structure and function, which in turn leads to tumorigenesis. We also discuss the clinical implications and review concepts of targeted treatments for these mutations. Continued research on CRF mutations will be critical for our future understanding of cancer biology and the development and implementation of novel cancer therapies. Cancer Res; 77(2); 227-33. ©2017 AACR.